Merck Resubmits Data to FDA for Ezetimibe/Atorvastatin ComboMerck Resubmits Data to FDA for Ezetimibe/Atorvastatin Combo

The resubmission of the updated new drug application includes the additional data requested by the FDA, and the company expects the FDA review to be completed in the first half of 2013. Heartwire

Source: Medscape Today Headlines - January 9, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news